Literature DB >> 2585214

Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children.

D J Safer1, R P Allen.   

Abstract

To determine whether the behavioral benefits of methylphenidate in hyperactive and inattentive children decline during long-term treatment, we analyzed data from 108 hyperactive students who responded well to methylphenidate therapy for 3 to 10 years. Responders were identified by their consistent improvement from baseline on standard teacher rating scales. The therapeutically effective drug doses were corrected for body size and evaluated in relation to increasing age and treatment duration. Body size corrections included milligrams per kilogram, milligrams per kilogram to the 0.7th power, and milligrams per square meter of estimated body surface area. The major findings were that (1) the dose of methylphenidate, when adjusted for growth, did not change significantly during the 3 to 10 years of treatment; (2) the loss of a previously satisfactory response to methylphenidate treatment was uncommon (6%) and when present was related to middle school enrollment, male gender, noncompliance with medication, and lower than customary dosage; (3) the dose calculations that minimized the effects of growth with age were milligrams per kilogram to the 0.7th power and milligrams per square meter of estimated body surface area; and (4) the commonly used milligrams per kilogram dose consistently overcorrected for growth with advancing age.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2585214     DOI: 10.1016/s0022-3476(89)80759-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats.

Authors:  Felipe Schmitz; Emilene Barros da Silva Scherer; Maira Jaqueline da Cunha; Aline Andrea da Cunha; Daniela Delwing Lima; Débora Delwing; Carlos Alexandre Netto; Angela Terezinha de Souza Wyse
Journal:  Mol Cell Biochem       Date:  2011-10-20       Impact factor: 3.396

2.  A review of long-acting medications for ADHD in Canada.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-11

Review 3.  Attention deficit hyperactivity disorder--a review.

Authors:  C Williams; B Wright; I Partridge
Journal:  Br J Gen Pract       Date:  1999-07       Impact factor: 5.386

Review 4.  Stimulant drugs.

Authors:  P J Santosh; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

5.  Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective.

Authors:  D J Safer
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

6.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

7.  Inhibition of mitochondrial respiratory chain in the brain of adult rats after acute and chronic administration of methylphenidate.

Authors:  Ana O Fagundes; Giselli Scaini; Patricia M Santos; Monique U Sachet; Nayara M Bernhardt; Gislaine T Rezin; Samira S Valvassori; Patrícia F Schuck; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2009-09-24       Impact factor: 3.996

8.  Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, striatum and hippocampus of juvenile rats.

Authors:  Felipe Schmitz; Emilene B S Scherer; Fernanda R Machado; Aline A da Cunha; Bárbara Tagliari; Carlos A Netto; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2012-09-12       Impact factor: 3.584

Review 9.  Risks and benefits of drugs used in the management of the hyperactive child.

Authors:  A M Fox; M J Rieder
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 10.  Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.

Authors:  Mark L Wolraich; Melissa A Doffing
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.